相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase (RT) Mutations on Nucleoside RT Inhibitor Susceptibility
George L. Melikian et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
A Review of the Virological Efficacy of the 4 World Health Organization-Recommended Tenofovir-Containing Regimens for Initial HIV Therapy
Michele W. Tang et al.
CLINICAL INFECTIOUS DISEASES (2012)
The HIVdb System for HIV-1 Genotypic Resistance Interpretation
Michele W. Tang et al.
INTERVIROLOGY (2012)
The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness
Rima Kulkarni et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis
Laurence Rimsky et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor
Tristan J. Barber et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G
Ana Carolina Palma et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Jean-Michel Molina et al.
LANCET INFECTIOUS DISEASES (2012)
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Jan van Lunzen et al.
LANCET INFECTIOUS DISEASES (2012)
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy
Derrick D. Goodman et al.
AIDS (2011)
Short Communication Prevalence of Susceptibility to Etravirine by Genotype and Phenotype in Samples Received for Routine HIV Type 1 Resistance Testing in the United States
Gaston Picchio et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2011)
Surveillance of Transmitted HIV Type 1 Drug Resistance Among HIV Type 1-Positive Women Attending an Antenatal Clinic in Kakinada, India
Smita R. Thorat et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2011)
Transmitted HIV Type 1 Drug Resistance Among Individuals with Recent HIV Infection in East and Southern Africa
Matt A. Price et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2011)
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens
Torsak Bunupuradah et al.
ANTIVIRAL THERAPY (2011)
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis
Erkki Lathouwers et al.
ANTIVIRAL THERAPY (2011)
A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes
Kathleen M. Doherty et al.
BMC BIOINFORMATICS (2011)
Deep Third Variable Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc
Luke C. Swenson et al.
CLINICAL INFECTIOUS DISEASES (2011)
Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B
Alexandra U. Scherrer et al.
CLINICAL INFECTIOUS DISEASES (2011)
Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors
Alexandra U. Scherrer et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals
Arkaitz Imaz et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients
Luke C. Swenson et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
Jose-Luis Blanco et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes
Vivek Jain et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir
Filippo Canducci et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations
Hong-Tao Xu et al.
JOURNAL OF VIROLOGY (2011)
Interaction of Reverse Transcriptase (RT) Mutations Conferring Resistance to Lamivudine and Etravirine: Effects on Fitness and RT Activity of Human Immunodeficiency Virus Type 1
Zixin Hu et al.
JOURNAL OF VIROLOGY (2011)
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
Calvin J. Cohen et al.
LANCET (2011)
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study
Raph L. Hamers et al.
LANCET INFECTIOUS DISEASES (2011)
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
Linda Wittkop et al.
LANCET INFECTIOUS DISEASES (2011)
Surveillance of Transmitted Antiretroviral Drug Resistance among HIV-1 Infected Women Attending Antenatal Clinics in Chitungwiza, Zimbabwe
Mqondisi Tshabalala et al.
PLOS ONE (2011)
Emergence and Persistence of Minor Drug-Resistant HIV-1 Variants in Ugandan Women after Nevirapine Single-Dose Prophylaxis
Andrea Hauser et al.
PLOS ONE (2011)
Sentinel Surveillance of HIV-1 Transmitted Drug Resistance, Acute Infection and Recent Infection
Hong-Ha M. Truong et al.
PLOS ONE (2011)
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine
Valerie F. Boltz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
Jose R. Arribas et al.
AIDS (2010)
Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, US-2006
William H. Wheeler et al.
AIDS (2010)
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies
Johan Vingerhoets et al.
AIDS (2010)
Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies
Lotke Tambuyzer et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors
Annie Talbot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
Soo-Yon Rhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in Japan
Junko Hattori et al.
ANTIVIRAL RESEARCH (2010)
Strand transfer inhibitors of HIV-1 integrase: Bringing IN new era of antiretroviral therapy
Damian J. McColl et al.
ANTIVIRAL RESEARCH (2010)
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score
Jonathan M. Schapiro et al.
ANTIVIRAL THERAPY (2010)
Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and Deep Sequencing to Plasma RNA and Proviral DNA
Luke C. Swenson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Antiretroviral Treatment of Adult HIV Infection 2010 Recommendations of the International AIDS Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Genotypic Tests for Determining Coreceptor Usage of HIV-1
D. R. Kuritzkes
JOURNAL OF INFECTIOUS DISEASES (2010)
Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication
Michael E. Abram et al.
JOURNAL OF VIROLOGY (2010)
Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009
Vivek Jain et al.
PLOS ONE (2010)
Molecular Basis for Drug Resistance in HIV-1 Protease
Akbar Ali et al.
VIRUSES-BASEL (2010)
Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase
Kamalendra Singh et al.
VIRUSES-BASEL (2010)
The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy
Mina C. Hosseinipour et al.
AIDS (2009)
The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy
Ruth Bridget Ferns et al.
AIDS (2009)
When and how to use maraviroc in HIV-infected patients
Vincent Soriano et al.
AIDS (2009)
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
Sandra De Meyer et al.
AIDS (2009)
The Association of HIV Susceptibility Testing With Survival Among HIV-Infected Patients Receiving Antiretroviral Therapy: A Cohort Study
Frank J. Palella et al.
ANNALS OF INTERNAL MEDICINE (2009)
Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy
Anna Maria Geretti et al.
CLINICAL INFECTIOUS DISEASES (2009)
High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial
Y. Yazdanpanah et al.
CLINICAL INFECTIOUS DISEASES (2009)
Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure
Francesca Cossarini et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Minority Variants Associated with Transmitted and Acquired HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance: Implications for the Use of Second-Generation Nonnucleoside Reverse Transcriptase Inhibitors
Vici Varghese et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug
Marc Wirden et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
Nilu Goonetilleke et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms
Soo-Yon Rhee et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe
Jurgen Vercauteren et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Response to Vicriviroc in Treatment-Experienced Subjects, as Determined by an Enhanced-Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211
Zhaohui Su et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment-Naive Patients Significantly Impact Treatment Outcomes
Birgitte B. Simen et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Signature Nucleotide Polymorphisms at Positions 64 and 65 in Reverse Transcriptase Favor the Selection of the K65R Resistance Mutation in HIV-1 Subtype C
Cedric F. Invernizzi et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1
Dimitrios Coutsinos et al.
JOURNAL OF VIROLOGY (2009)
Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways
Signe Fransen et al.
JOURNAL OF VIROLOGY (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy
Paul E. Sax et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
Olivier Delelis et al.
NUCLEIC ACIDS RESEARCH (2009)
A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors
John P. Moore et al.
CURRENT OPINION IN HIV AND AIDS (2009)
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
Jean-Fran Ois Delfraissy et al.
AIDS (2008)
Effect of Baseline Viral Susceptibility on Response to Darunavir/Ritonavir versus Control Protease Inhibitors in Treatment-Experienced HIV Type 1-Infected Patients: POWER 1 and 2
Anton Pozniak et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2008)
Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: A systematic review of clinical trials
Ravindra Gupta et al.
CLINICAL INFECTIOUS DISEASES (2008)
Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel
Martin S. Hirsch et al.
CLINICAL INFECTIOUS DISEASES (2008)
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects
Daniel R. Kuritzkes et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and erntricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Jean-Michel Molina et al.
LANCET (2008)
Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection
Gerd Faetkenheuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
David A. Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Identification and characterisation of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors
Nicolas Sluis-Cremer et al.
VIRUS RESEARCH (2008)
Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase
Jingshan Ren et al.
VIRUS RESEARCH (2008)
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy
Jeffrey A. Johnson et al.
PLOS MEDICINE (2008)
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
Andrea De Luca et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz
Katyna Borroto-Esoda et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance
Chunlin Wang et al.
GENOME RESEARCH (2007)
Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: Population and clonal sequence analysis
Seble Kassaye et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase
Urvi M. Parikh et al.
AIDS (2007)
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN:: a randomised controlled phase III trial
Jose Valdez Madruga et al.
LANCET (2007)
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
Soo-Yon Rhee et al.
PLOS COMPUTATIONAL BIOLOGY (2007)
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:: a pooled subgroup analysis of data from two randomised trials
Bonaventura Clotet et al.
LANCET (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211
Timothy J. Wilkin et al.
CLINICAL INFECTIOUS DISEASES (2007)
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
Jeannette M. Whitcomb et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Interruption of enfuvirtide in HIV-1-Infected adults with incomplete viral suppression on an enfuvirtide-based regimen
Steven G. Deeks et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world
Diane E. Bennett
CURRENT OPINION IN INFECTIOUS DISEASES (2006)
Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen
Cecilia Cabrera et al.
AIDS (2006)
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1 - Infected patients with detectable viremia
Peter W. Hunt et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis
Jing Lu et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
Edwin DeJesus et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
Robert S. Hogg et al.
PLOS MEDICINE (2006)
HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL
Yumi Mitsuya et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Short-term antiviral activity of TMC278 -: a novel NNRTI -: in treatment-naive HIV-1-infected subjects
Frank Goebel et al.
AIDS (2006)
HIV-1 coreceptor use in triple-class treatment experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response
Tom Melby et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation
S. Boucher et al.
HIV MEDICINE (2006)
HIV tropism:: diagnostic tools and implications for disease progression and treatment with entry inhibitors
Eva Poveda et al.
AIDS (2006)
Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations
Aravind Basavapathruni et al.
BIOCHEMISTRY (2006)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing
M Oette et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatmentexperienced patients
LK Naeger et al.
AIDS (2006)
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study
P Cane et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 clinical trials
M Nelson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G
AB Abecasis et al.
AIDS (2005)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection
SG Deeks et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe:: Implications for clinical management
AMJ Wensing et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals
ZL Brumme et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
TB Campbell et al.
CLINICAL INFECTIOUS DISEASES (2005)
Low accumulation of L90M in protease from subtype FHIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism
A Calazans et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
HIV-1 drug resistance: Degree of underestimation by a cross-sectional versus a longitudinal testing approach
PR Harrigan et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Comparison of the precision and sensitivity of the antivirogram and PhenoSense HIV drug susceptibility assays
J Zhang et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: A randomized placebo-controlled trial
JM Molina et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Integrase inhibitors to treat HIV/AIDS
Y Pommier et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine
D Lecossier et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis
S Palmer et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20)
J Lu et al.
JOURNAL OF VIROLOGY (2004)
Genetic variation at NNRT1 resistance-associated positions in patients infected with HIV-1 subtype C
Z Grossman et al.
AIDS (2004)
Dynamics of HIV-1 recombination in its natural target cells
DN Levy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients
MD Miller et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates
PR Sista et al.
AIDS (2004)
Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment
S Menzo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Persistence of mutidrug-resistant HIV-1 in primary infection leading to superinfection
B Brenner et al.
AIDS (2004)
Long-term persistence of primary genotypic resistance after HIV-1 seroconversion
D Pao et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial
JE Gallant et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure
AG Marcelin et al.
JOURNAL OF MEDICAL VIROLOGY (2004)
Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20
AG Marcelin et al.
AIDS (2004)
Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate
DJ McColl et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-base analysis of diverse human immunodeficiency virus type 1 strains
SH Eshleman et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2004)
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens
R Colonno et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen
SUC Sankatsing et al.
AIDS (2003)
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals
M Louie et al.
AIDS (2003)
Performance characteristics of the TRUGENE HIV-1 genotyping kit and the opengene DNA sequencing system
DR Kuritzkes et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors
B Brenner et al.
AIDS (2003)
HIV mutagenesis and the evolution of antiretroviral drug resistance
LM Mansky
DRUG RESISTANCE UPDATES (2002)
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates
JM Whitcomb et al.
AIDS (2002)
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure
A Antinori et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2002)
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults
JM Kilby et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2002)
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
A Trkola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1
W Sugiura et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom
PA Cane et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Genotypic and penotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT):: Multicenter study of patients treated with RT inhibitors
B Masquelier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy
L Bacheler et al.
JOURNAL OF VIROLOGY (2001)
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
RL Murphy et al.
AIDS (2001)
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase
AS Espeseth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues
K Van Vaerenbergh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir
R Ziermann et al.
JOURNAL OF VIROLOGY (2000)
分享论文
